LeMaitre Vascular (NASDAQ:LMAT) Price Target Raised to $127.00

LeMaitre Vascular (NASDAQ:LMAT) had its target price hoisted by Citizens Jmp from $118.00 to $127.00 in a research report released on Wednesday,Benzinga reports. They currently have a market outperform rating on the medical instruments supplier’s stock.

Several other equities analysts also recently issued reports on the stock. Barrington Research boosted their price target on shares of LeMaitre Vascular from $95.00 to $105.00 and gave the company an “outperform” rating in a report on Thursday, February 26th. Freedom Capital raised shares of LeMaitre Vascular to a “hold” rating in a report on Tuesday, March 31st. Weiss Ratings raised shares of LeMaitre Vascular from a “hold (c+)” rating to a “buy (b-)” rating in a report on Tuesday, March 10th. Wells Fargo & Company boosted their price target on shares of LeMaitre Vascular from $94.00 to $104.00 and gave the company an “equal weight” rating in a report on Wednesday. Finally, Roth Mkm reissued a “buy” rating and set a $117.00 price target (up from $108.00) on shares of LeMaitre Vascular in a report on Thursday, February 26th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, LeMaitre Vascular presently has a consensus rating of “Moderate Buy” and an average price target of $112.60.

LeMaitre Vascular Stock Performance

LeMaitre Vascular stock opened at $107.94 on Wednesday. The company has a market cap of $2.47 billion, a PE ratio of 39.83, a P/E/G ratio of 3.00 and a beta of 0.60. The company has a fifty day moving average price of $110.00 and a two-hundred day moving average price of $94.48. The company has a debt-to-equity ratio of 0.42, a current ratio of 14.32 and a quick ratio of 10.95. LeMaitre Vascular has a 12 month low of $78.35 and a 12 month high of $118.01.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings results on Tuesday, May 5th. The medical instruments supplier reported $0.68 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.66 by $0.02. LeMaitre Vascular had a net margin of 24.35% and a return on equity of 15.36%. The company had revenue of $66.55 million during the quarter, compared to the consensus estimate of $66.67 million. During the same quarter in the previous year, the company posted $0.48 earnings per share. The company’s revenue for the quarter was up 11.1% compared to the same quarter last year. LeMaitre Vascular has set its FY 2026 guidance at 2.930-3.080 EPS and its Q2 2026 guidance at 0.790-0.840 EPS. Research analysts expect that LeMaitre Vascular will post 3 earnings per share for the current year.

LeMaitre Vascular Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, June 4th. Investors of record on Thursday, May 21st will be issued a $0.25 dividend. The ex-dividend date of this dividend is Thursday, May 21st. This represents a $1.00 annualized dividend and a yield of 0.9%. LeMaitre Vascular’s dividend payout ratio is presently 36.90%.

Insider Buying and Selling

In related news, CEO George W. Lemaitre sold 55,930 shares of the company’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $107.81, for a total value of $6,029,813.30. Following the completion of the sale, the chief executive officer owned 1,476,500 shares of the company’s stock, valued at $159,181,465. This represents a 3.65% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Trent G. Kamke sold 1,044 shares of the company’s stock in a transaction dated Friday, February 27th. The stock was sold at an average price of $110.29, for a total transaction of $115,142.76. Following the completion of the sale, the insider directly owned 6,677 shares of the company’s stock, valued at $736,406.33. The trade was a 13.52% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 215,438 shares of company stock valued at $23,062,911 over the last 90 days. 7.40% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On LeMaitre Vascular

Institutional investors have recently bought and sold shares of the stock. Sound Income Strategies LLC lifted its holdings in LeMaitre Vascular by 425.6% in the first quarter. Sound Income Strategies LLC now owns 226 shares of the medical instruments supplier’s stock worth $25,000 after purchasing an additional 183 shares during the period. Cornerstone Planning Group LLC lifted its holdings in LeMaitre Vascular by 534.0% in the third quarter. Cornerstone Planning Group LLC now owns 336 shares of the medical instruments supplier’s stock worth $30,000 after purchasing an additional 283 shares during the period. Catalyst Capital Advisors LLC acquired a new stake in LeMaitre Vascular in the first quarter worth about $32,000. MAI Capital Management bought a new stake in LeMaitre Vascular in the third quarter worth about $38,000. Finally, First Horizon Corp bought a new stake in LeMaitre Vascular in the third quarter worth about $39,000. Institutional investors and hedge funds own 84.64% of the company’s stock.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.